In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Read More ›

Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens. Read More ›

Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›

Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›

An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›

The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed. Read More ›

Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results. Read More ›

Heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) derived significant benefit from a combination of daratumumab, dexamethasone, and bortezomib. These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM. Read More ›

Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.

Read More ›

In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.

Read More ›